海普瑞：2023年報.pdf

1、2023 Annual Report年度報告(A joint stock company incorporated in the Peoples Republic of China with limited liability)Stock Code 股份代號:9989（於中華人民共和國註冊成立的股份有限公司）年度報告Annual Report 2023Corporate Information 2公司資料Financial Highlights 5財務摘要Chairmans Statement 6董事長致辭Management Discussion and Analysis 10管理層討論與分

2、析Directors,Supervisors and Senior Management 28董事、監事及高級管理層Directors Report 34董事會報告Corporate Governance Report 61企業管治報告CONTENTS目 錄Independent Auditors Report 84獨立核數師報告Consolidated Statement of Profit or Loss 96綜合損益表Consolidated Statement of Comprehensive Income 97綜合全面收益表Consolidated Statement of Fina

3、ncial Position 98綜合財務狀況表Consolidated Statement of Changes in Equity 100綜合權益變動表Consolidated Statement of Cash Flows 102綜合現金流量表Notes to Financial Statements 106財務報表附註SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO.,LTD.深圳市海普瑞藥業集團股份有限公司2Corporate Information公司資料Board of DirectorsExecutive DirectorsMr.Li Li(C

4、hairman)Ms.Li Tan(Deputy General Manager)Mr.Shan Yu(General Manager)Mr.Zhang Ping(appointed on May 22,2023)Independent Non-executive DirectorsDr.Lu ChuanMr.Huang Peng(appointed on May 22,2023)Mr.Yi Ming(appointed on May 22,2023)Mr.Chen Junfa(retired on May 22,2023)Mr.Wang Zhaohui(retired on May 22,2

5、023)Joint Company SecretariesMr.Qian FengqiMs.Chan Sze Ting(FCG,HKFCG)Authorized RepresentativesMr.Qian FengqiMs.Chan Sze TingSupervisorsMr.Zheng Zehui(Chairman)Ms.Tang HaijunMs.Su Jilan(Employee Supervisor)Strategy CommitteeMr.Li Li(Chairman)Ms.Li TanDr.Lu ChuanRemuneration and Evaluation Committee

6、Mr.Yi Ming(Chairman)(appointed on May 22,2023)Mr.Li LiMr.Huang Peng(appointed on May 22,2023)Mr.Wang Zhaohui(retired on May 22,2023)Mr.Chen Junfa(retired on May 22,2023)董事會執行董事李鋰先生（董事長）李坦女士（副總經理）單宇先生（總經理）張平先生（於二零二三年五月二十二日獲委任）獨立非執行董事呂川博士黃鵬先生（於二零二三年五月二十二日獲委任）易銘先生（於二零二三年五月二十二日獲委任）陳俊發先生（於二零二三年五月二十二日退任）王